Elios Vision

Executive Summary

Elios Vision is a private medical device company based in Irvine, California, developing the ELIOS procedure, a novel minimally invasive glaucoma surgery (MIGS) that uses an excimer laser to create micro-openings in the trabecular meshwork. The procedure is designed to be performed concurrently with cataract surgery, addressing two major age-related eye conditions in a single surgical setting. Founded in 2017, the company aims to provide a safe and effective treatment for glaucoma patients, potentially reducing the need for multiple surgeries and improving outcomes. The ELIOS technology differentiates itself from other MIGS devices by utilizing a precise laser ablation approach to enhance aqueous outflow without implanting a foreign body, which may lower the risk of complications and revision surgeries.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for expanded indication or 510(k) clearance for ELIOS device modifications75% success
• TBDPublication of pivotal clinical trial results demonstrating long-term efficacy and safety80% success
• H1 2026Strategic partnership or distribution agreement with a major ophthalmic company60% success